News Column

Genmab Announces DuoBody and HexaBody Platform Collaboration with Undisclosed Biotechnology Company

June 9, 2014

"We are enthusiastic to enter our first research collaboration for the HexaBody technology which was unveiled just over a year ago. This exciting technology has the potential to enhance antibody efficacy in a fundamentally new way. We are also very pleased to enter another DuoBody platform collaboration and we look forward to exploring the therapeutic potential of products incorporating the HexaBody and DuoBody technologies with this major Biotechnology company," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

The financial terms of the agreement have not been disclosed. This agreement will not have a material impact on Genmab's financial results and cash position.

For more stories covering the world of technology, please see HispanicBusiness' Tech Channel

Source: Global Data Point

Story Tools Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters